By Karen Roman Oculis Holding AG (Nasdaq: OCS) said Phase 2 of its neuroprotective candidate OCS-05 met key endpoints of ...

Tobacco and coffee contain bioactive compounds that may reduce Parkinson's disease risk by targeting key pathways such as MAO ...

Recent studies have identified the significance of mitophagy, a quality control process that removes dysfunctional ...

The primary safety endpoint was carried out through the percentage of patients with shift from normal (at baseline) to ...

High-density lipoprotein (HDL) cholesterol may help conserve healthy brain matter in middle-aged adults, according to a study ...

Oculis Holding’s OCS-05 phase 2 ACUITY trial in acute optic neuritis meets primary safety endpoint and key secondary efficacy endpoints: Zug, Switzerland Tuesday, January 7, 202 ...

The primary safety endpoint was carried out through the percentage of patients with shift from normal (at baseline) to ...

The intricate connection between gut health and brain function is increasingly capturing scientific interest. A ...

The trial is designed to assess the tolerability, efficacy, and safety of two different dosages of the therapy.

Oculis’ peptidomimetic small molecule has been shown to help protect the eyes of patients with inflammation of the optic ...

Published extended data from the phase 2 EMPhASIS trial of vidofludimus calcium in relapsing-remitting MS in the peer reviewed journal, Neurology® Neuroimmunology & Neuroinflammation, an official ...